Stock price

Discussion in 'Acorda Therapeutics' started by anonymous, Mar 19, 2020 at 2:29 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Scopia read far too greedy.
     

  2. anonymous

    anonymous Guest

    Cafepharma posts are the last thing driving down share price LMAO
    Let’s talk about RC, LS (Laura Lol) and BOD.
    These posts aren’t even written by people that work at Acorda.
     
  3. anonymous

    anonymous Guest

    RC didn’t develop Inbrija. Civitas did!
     
  4. anonymous

    anonymous Guest



    BS !! Lets be honest here, Dr Cohen was instrumental in the development of Inbrija and ALL inhaled LD therapeutics !
     
  5. anonymous

    anonymous Guest

    The Wall Street pharmaceutical financial advisors study posts on Cafepharma and other sites judiciously. Anytime you bash ACOR you likely see a reaction in shareprice...driving it down. This is an unfortunate situation as many of the bashers do not work here.
     
  6. anonymous

    anonymous Guest

    habib, you are the only one who’s Wall Street “pros” get their info from CP.

    could explain the share price. I’m shocked they haven’t bought on your routine upbeat (albeit made up) posts.

    Hey, I missed RC today when they were talking to Regeneron about what they are doing to develop treatment for the Wuhan virus. He must have been busy critiquing others on social media.
     
  7. anonymous

    anonymous Guest

    INSTRUMENTAL!!!!
    <<<< LMAO >>>>

    That credit solely goes to Batycky, Freed & Murck
     
  8. anonymous

    anonymous Guest

    Now you know why Big Pharma is targeting Acorda "50 percent more people in those years got Parkinson's"

    WHAT !! INBRIJA MARKET EXPANDS DRAMATICALLY POST CORONAVIRUS !!!!!!! BLOCKBUSTER CITY !!!!!

    Come on Pfizer baby !!
     
  9. anonymous

    anonymous Guest

    Very Profound post. Yes Inbrija is the pharma equivalent of the Blackbeard's Treasure. Pfiza will pay whatever it takes to own this gem. Thank You Dr Cohen.
     
  10. anonymous

    anonymous Guest

    You would have more success paying Pfizer to take this product before you go bankrupt. RC has run out of window dressing tricks, deferring debt, downsize, launch failure, heavy rebates to pay for access, horrific GTN, and more excuses than a prostitute going to jail. Your dependent on all other parlour tricks and hope for a sale at $2 due to a lapse in execution on a product that’s almost 2 years on market.
     
  11. anonymous

    anonymous Guest

    “Acorda Therapeutics said today it will acquire Civitas Therapeutics for $525 million cash, in a deal that gives the neurological treatment worldwide rights to the Phase III Parkinson’s disease drug candidate CVT-301.”
    Sounds like he slightly overpaid.
     
  12. anonymous

    anonymous Guest

    The only negative posts come after all your BS and false posting. If you notice, when the paid PR gets fired and stops posting basically no one posts! You create the negativity.
     
  13. anonymous

    anonymous Guest

    The acquisition ends an unusual biotech path for Civitas. The story started with a big investment by Alkermes years ago in a Chelsea facility built to make inhalable insulin for diabetics. That program was part of a partnership with Eli Lilly, but Lilly scrapped it in 2008. Alkermes then spun out the technology that was to be used in the program by forming Civitas, which secured $20 million in financing led by Canaan and Longitude to get going.

    Civitas didn’t try to continue the inhalable insulin effort. Instead, it turned its attention to using its technology to developing inhalable L-dopa, known as CVT-301, as an adjunct therapy to the pills a majority of Parkinson’s patients take to manage their symptoms.

    RC has zero influence in developing inbrija. He just overpaid.
     
  14. anonymous

    anonymous Guest

    it was dr harold murck that successfully navigated all the phase 3 studies that enabled acorda to filed the nda and eventually the approval

    give the chap the credit he deserves.
     
  15. anonymous

    anonymous Guest

    Inbrija, the gift that keeps on giving.

    from one companies fire sale to another.
     
  16. anonymous

    anonymous Guest


    uh no - ALLLLLL posts are from employees who r looking to leave this shithole.
     
  17. anonymous

    anonymous Guest

    Congratulations indeed... you have hit an all time low intraday of $0.79. Amazing group who now resort to hope of some sucker buying this POS for $2 share. Your current market cap is a rounding error in Pharma space. Rock on... you will be quarantined and unemployed soon.
     
  18. anonymous

    anonymous Guest

    I expect RC will be blaming the Wuhan virus for his failings while seeking a government bailout.
     
  19. anonymous

    anonymous Guest

    dont see that scenario as ACOR will rebound big time shortly with pfiza m&a
     
  20. anonymous

    anonymous Guest

    Any rebound would be driven by the purchasing suitor.. and NOT anything Acorda has executed. And a sale at even up to $4 a share is hardly a rebound based on the thousands of investors who bought into your charade at $30 a share.